CoChat

Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo‐controlled trial

Aubin, H. J., Lebargy, F., Berlin, I., Bidaut‐Mazel, C., Chemali‐Hudry, J., Lagrue, G. · 2004 · Addiction
Cited by 68

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background Previous published studies assessed the efficacy of bupropion in smoking cessation only in North American populations of smokers. Results of therapeutic drug trials are not always directly applicable in other populations. Aims To confirm the efficacy of bupropion in smoking cessation in European smokers. Design A multi‐centre, randomized, double‐blind placebo‐controlled trial. Setting Seventy‐four smoking cessation out‐patient clinics in France. Participants The study included 509 smokers motivated to quit smoking. Intervention Subjects were randomized to either slow‐release bupropion 150 mg b.i.d. (B) or to placebo (Pl) in a 2 : 1 ratio, treated for 7 weeks, and followed‐up for 26 weeks. Measurements Main outcome measure: 6 months’ point prevalence abstinence, determined by self‐report and expired air carbon monoxide measurement. Secondary outcome measures: weeks 4–7 and weeks 4–26 continuous abstinence rates, craving, withdrawal symptoms, weight and cigarette consumption in smokers unable to quit. Adverse events were recorded systematically. Findings Six months’ point prevalence abstinence rates were 31% and 16%[odds ratio = 2.3, confidence interval (CI) 95%: 1.4–3.7] in the B and Pl groups, respectively. Continuous abstinence rates were 41% (B) and 21% (P) with OR = 2.5 (CI 95%: 1.6–3.9) for weeks 4–7, and 25% (B) and 13% (P) with OR = 2.2 (CI 95%: 1.3–3.6) for weeks 4–26, respectively. Craving decreased significantly more with B than with Pl during treatment period, but there was no difference for total withdrawal symptoms score. Abstinent subjects gained significantly less weight at week 7 with B than with Pl. Low level of nicotine dependence, high motivation, absence of smoking‐related disease, long duration of previous quit attempts, male gender, low level of current alcohol problems and living as a couple were predictive of successful cessation. With the exception of marital status, no interaction was observed between any of these predictive factors and the efficacy of bupropion. More of those who continued smoking in the B group than the P group reduced their consumption by at least 50%. Conclusions Sustained‐release bupropion is efficacious as an aid to smoking cessation in European smokers. No outcome predictors were identified that might indicate that certain subgroups of smokers would benefit more than others from treatment with bupropion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1360-0443.2004.00814.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 68

Metadata

Authors
Aubin, H. J., Lebargy, F., Berlin, I., Bidaut‐Mazel, C., Chemali‐Hudry, J., & Lagrue, G.
Venue
Addiction
Publisher
Wiley
Published
2004-08-18
Volume
99
Issue
9
Pages
1206-1218
ISSN
  • 0965-2140 (ISSN-L)
  • 1360-0443
OpenAlex
W2086542708
Cited by
68
References
9
FWCI
2.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/j.1360-0443.2004.00814.x
The paper
Aubin, H. J., Lebargy, F., Berlin, I., Bidaut‐Mazel, C., Chemali‐Hudry, J., & Lagrue, G. (2004). Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo‐controlled trial. Addiction. https://doi.org/10.1111/j.1360-0443.2004.00814.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.